Press Releases

07.05.2022
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®
07.01.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06.10.2022
Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
06.02.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05.17.2022
Iveric Bio to Present at the UBS Global Healthcare Conference 2022
05.16.2022
Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference
05.04.2022
Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results
05.04.2022
Iveric Bio Announces Presentation of Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
05.03.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04.27.2022
Iveric Bio to Report First Quarter 2022 Financial Results and Host Conference Call on Wednesday, May 4, 2022